Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Research Solutions

Neither a doctor nor a teaching hospital

Research payments

$3,773,719

337 payments

Through program year 2025, Clinical Research Solutions is reported as receiving $3,773,719 in research payments, across 337 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $3,844 16
2024 Research $266,583 6
2023 Research $357,893 15
2022 Research $674,939 51
2021 Research $527,092 118
2020 Research $529,736 67
2019 Research $1,413,632 64

Breakdown

Who paid Research payments · program years 2019–2025
  1. Medivation Inc. $1,109,711 26 payments
  2. Romark Laboratories, LC $979,212 4 payments
  3. Pfizer Inc. $909,151 44 payments
  4. GlaxoSmithKline, LLC. $183,456 44 payments
  5. Genentech, Inc. $127,185 25 payments
  6. Myovant Sciences Inc. $119,932 20 payments
  7. AbbVie, Inc. $88,650 48 payments
  8. Urovant Sciences Inc $73,120 20 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $42,456 17 payments
  10. Shionogi Inc $20,615 12 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Randomized Efficacy and Safety Study of Enzalutamide Plus Leuprolide Enzalutamide Monotherapy and Placebo Plus Leuprolide in Men With Highrisk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy $1,376,295 32 payments
  2. A Phase III Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide and Nitazoxanide Plus Oseltamivir in the Treatment of Acute Uncomplicated Influenza $494,618 2 payments
  3. Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection $484,594 2 payments
  4. A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib With Enzalutamide in Metastatic Castrationresistant Prostate Cancer $299,221 10 payments
  5. A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib in Combination With Physicians Choice of Enzalutamide Or Abiraterone Acetateprednisone in Metastatic Castrationresistant Prostate Cancer With Dna Damage Repair Deficiencies $256,312 7 payments
  6. A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, DO $170,956 38 payments
  7. Transmission Study Household $127,185 25 payments
  8. Hero Study Grant $119,932 20 payments
  9. A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib in Combination With Physicians Choice of Enzalutamide Or Abiraterone Acetateprednisone in Metastatic Castrationresistant Prostate Cancer With Dna Damage Repair Deficiencies $84,978 20 payments
  10. A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) $72,014 16 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $28,670 7 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record